Skip to main content

Advertisement

SpringerLink
Log in

Approach for chemosensitization of cisplatin-resistant ovarian cancer by cucurbitacin B

  • Original Article
  • Published:
Tumor Biology

Abstract

Ovarian cancer is the most deadly gynecological cancer. The first line in treatment is platinum-based drugs. However, most patients suffer from tumor recurrence, characterized by resistance to cisplatin. A plausible approach to address the tumor resistance is to co-administer the chemotherapeutic agents along with natural products to offer a synergistic effect and optimize the dosage regimen. Cucurbitacin B is a natural product and displays antitumor activity against a wide array of cancer cell lines. The aim of this work is to determine the antitumor activity against ovarian cancer cell line (A2780) and possible sensitization activity on cisplatin-resistant cell line (A2780CP) in 2D and 3D culture model. 3D spheroids were generated from A2780CP cell line. A2780, A2780CP, and the spheroids were treated with cucurbitacin B, cisplatin alone, or pretreated with cucurbitacin B followed by cisplatin. The viability, cell cycle, and apoptosis were analyzed. Level of ROS and total glutathione was measured. In this study, cucurbitacin B showed cytotoxicity against the ovarian cancer cell lines, and pretreatment of A2780CP cells leads to a significant increase in the cytotoxicity of cisplatin. The mechanism behind the sensitization effect was dependent in part on the depletion of the total glutathione, an increase in ROS through a decrease in the level of dual-specificity tyrosine-regulated kinase (Dyrk1B), decrease in pERK1/2 and pSTAT3 level. The viability of spheroids treated with a combination of cisplatin and cucurbitacin B were significantly decreased. The resulting data shows that cucurbitacin B is a promising chemosensitizer for the cisplatin-resistant ovarian cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7

Similar content being viewed by others

References

  1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69–90. doi:10.3322/caac.20107.

    Article  PubMed  Google Scholar 

  2. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin. 2009;59(4):225–49. doi:10.3322/caac.20006.

    Article  PubMed  Google Scholar 

  3. Iwanicki MP, Davidowitz RA, Ng MR, Besser A, Muranen T, Merritt M, et al. Ovarian cancer spheroids use myosin-generated force to clear the mesothelium. Cancer Discov. 2011;1(2):144–57. doi:10.1158/2159-8274.cd-11-0010.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Nederman T, Acker H, Carlsson J. Penetration of substances into tumor tissue: a methodological study with microelectrodes and cellular spheroids. In Vitro. 1983;19(6):479–88.

    Article  CAS  PubMed  Google Scholar 

  5. Rebucci M, Michiels C. Molecular aspects of cancer cell resistance to chemotherapy. Biochem Pharmacol. 2013;85(9):1219–26. doi:10.1016/j.bcp.2013.02.017.

    Article  CAS  PubMed  Google Scholar 

  6. Stewart DJ. Mechanisms of resistance to cisplatin and carboplatin. Crit Rev Oncol Hematol. 2007;63(1):12–31. doi:10.1016/j.critrevonc.2007.02.001.

    Article  PubMed  Google Scholar 

  7. Mercurio F, Manning AM. Multiple signals converging on NF-kappaB. Curr Opin Cell Biol. 1999;11(2):226–32.

    Article  CAS  PubMed  Google Scholar 

  8. Karin M, Lin A. NF-kappaB at the crossroads of life and death. Nat Immunol. 2002;3(3):221–7. doi:10.1038/ni0302-221.

    Article  CAS  PubMed  Google Scholar 

  9. Hua Y, Jove R. The STATs of cancer—new molecular targets come of age. Nat Rev Cancer. 2004;4(2):97–105. doi:10.1038/nrc1275.

    Article  Google Scholar 

  10. Meinhold-Heerlein I, Bauerschlag D, Hilpert F, Dimitrov P, Sapinoso LM, Orlowska-Volk M, et al. Molecular and prognostic distinction between serous ovarian carcinomas of varying grade and malignant potential. Oncogene. 2005;24(6):1053–65. doi:10.1038/sj.onc.1208298.

    Article  CAS  PubMed  Google Scholar 

  11. Duan Z, Foster R, Bell DA, Mahoney J, Wolak K, Vaidya A, et al. Signal transducers and activators of transcription 3 pathway activation in drug-resistant ovarian cancer. Clin Cancer Res. 2006;12(17):5055–63. doi:10.1158/1078-0432.ccr-06-0861.

    Article  CAS  PubMed  Google Scholar 

  12. Han Z, Feng J, Hong Z, Chen L, Li W, Liao S, et al. Silencing of the STAT3 signaling pathway reverses the inherent and induced chemoresistance of human ovarian cancer cells. Biochem Biophys Res Commun. 2013;435(2):188–94. doi:10.1016/j.bbrc.2013.04.087.

    Article  CAS  PubMed  Google Scholar 

  13. Platanias LC. Map kinase signaling pathways and hematologic malignancies. Blood. 2003;101(12):4667–79. doi:10.1182/blood-2002-12-3647.

    Article  CAS  PubMed  Google Scholar 

  14. Lu Z, Xu S. ERK1/2 MAP kinases in cell survival and apoptosis. IUBMB Life. 2006;58(11):621–31. doi:10.1080/15216540600957438.

    Article  CAS  PubMed  Google Scholar 

  15. Kim KY, Choi KC, Park SH, Auersperg N, Leung PC. Extracellular signal-regulated protein kinase, but not c-Jun N-terminal kinase, is activated by type II gonadotropin-releasing hormone involved in the inhibition of ovarian cancer cell proliferation. J Clin Endocrinol Metab. 2005;90(3):1670–7. doi:10.1210/jc.2004-1636.

    Article  CAS  PubMed  Google Scholar 

  16. Hayakawa J, Ohmichi M, Kurachi H, Ikegami H, Kimura A, Matsuoka T, et al. Inhibition of extracellular signal-regulated protein kinase or c-Jun N-terminal protein kinase cascade, differentially activated by cisplatin, sensitizes human ovarian cancer cell line. J Biol Chem. 1999;274(44):31648–54.

    Article  CAS  PubMed  Google Scholar 

  17. Wulfkuhle JD, Aquino JA, Calvert VS, Fishman DA, Coukos G, Liotta LA, et al. Signal pathway profiling of ovarian cancer from human tissue specimens using reverse-phase protein microarrays. Proteomics. 2003;3(11):2085–90. doi:10.1002/pmic.200300591.

    Article  CAS  PubMed  Google Scholar 

  18. Bast Jr RC. Molecular approaches to personalizing management of ovarian cancer. Ann Oncol. 2011;22 Suppl 8:viii5–viii15. doi:10.1093/annonc/mdr516.

    Article  PubMed  PubMed Central  Google Scholar 

  19. Hu J, Friedman E. Depleting mirk kinase increases cisplatin toxicity in ovarian cancer cells. Genes Cancer. 2010;1(8):803–11. doi:10.1177/1947601910377644.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Lai GM, Ozols RF, Young RC, Hamilton TC. Effect of glutathione on DNA repair in cisplatin-resistant human ovarian cancer cell lines. J Natl Cancer Inst. 1989;81(7):535–9.

    Article  CAS  PubMed  Google Scholar 

  21. Hockenbery DM, Oltvai ZN, Yin XM, Milliman CL, Korsmeyer SJ. Bcl-2 functions in an antioxidant pathway to prevent apoptosis. Cell. 1993;75(2):241–51.

    Article  CAS  PubMed  Google Scholar 

  22. Chen X, Bao J, Guo J, Ding Q, Lu J, Huang M, et al. Biological activities and potential molecular targets of cucurbitacins: a focus on cancer. Anticancer Drugs. 2012;23(8):777–87. doi:10.1097/CAD.0b013e3283541384.

    Article  CAS  PubMed  Google Scholar 

  23. Alghasham AA. Cucurbitacins - a promising target for cancer therapy. Int J Health Sci. 2013;7(1):77–89.

    Article  Google Scholar 

  24. Chen JC, Chiu MH, Nie RL, Cordell GA, Qiu SX. Cucurbitacins and cucurbitane glycosides: structures and biological activities. Nat Prod Rep. 2005;22(3):386–99. doi:10.1039/b418841c.

    Article  CAS  PubMed  Google Scholar 

  25. Chen W, Leiter A, Yin D, Meiring M, Louw VJ, Koeffler HP. Cucurbitacin B inhibits growth, arrests the cell cycle, and potentiates antiproliferative efficacy of cisplatin in cutaneous squamous cell carcinoma cell lines. Int J Oncol. 2010;37(3):737–43.

    PubMed  Google Scholar 

  26. Iwanski GB, Lee DH, En-Gal S, Doan NB, Castor B, Vogt M, et al. Cucurbitacin B, a novel in vivo potentiator of gemcitabine with low toxicity in the treatment of pancreatic cancer. Br J Pharmacol. 2010;160(4):998–1007. doi:10.1111/j.1476-5381.2010.00741.x.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Lee DH, Thoennissen NH, Goff C, Iwanski GB, Forscher C, Doan NB, et al. Synergistic effect of low-dose cucurbitacin B and low-dose methotrexate for treatment of human osteosarcoma. Cancer Lett. 2011;306(2):161–70. doi:10.1016/j.canlet.2011.03.001.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Friedrich J, Seidel C, Ebner R, Kunz-Schughart LA. Spheroid-based drug screen: considerations and practical approach. Nat Protoc. 2009;4(3):309–24. doi:10.1038/nprot.2008.226.

    Article  CAS  PubMed  Google Scholar 

  29. Tung YC, Hsiao AY, Allen SG, Torisawa YS, Ho M, Takayama S. High-throughput 3D spheroid culture and drug testing using a 384 hanging drop array. Analyst. 2011;136(3):473–8. doi:10.1039/c0an00609b.

    Article  CAS  PubMed  Google Scholar 

  30. Hamaguchi K, Godwin AK, Yakushiji M, O'Dwyer PJ, Ozols RF, Hamilton TC. Cross-resistance to diverse drugs is associated with primary cisplatin resistance in ovarian cancer cell lines. Cancer Res. 1993;53(21):5225–32.

    CAS  PubMed  Google Scholar 

  31. Bartalis J, Halaweish FT. In vitro and QSAR studies of cucurbitacins on HepG2 and HSC-T6 liver cell lines. Bioorg Med Chem. 2011;19(8):2757–66. doi:10.1016/j.bmc.2011.01.037.

    Article  CAS  PubMed  Google Scholar 

  32. Alfadda AA, Sallam RM. Reactive oxygen species in health and disease. J Biomed Biotechnol. 2012;2012:936486. doi:10.1155/2012/936486.

    Article  PubMed  PubMed Central  Google Scholar 

  33. Chou TC, Martin N. CompuSyn for drug combinations: PC software and user’s guide: a computer program for quantitation of synergism and antagonism in drug combinations, and the determination of IC50 and ED50 and LD50 Values, ComboSyn Inc, Paramus, (NJ), 2005.

  34. Tait SWG, Green DR. Mitochondria and cell death: outer membrane permeabilization and beyond. Nat Rev Mol Cell Biol. 2010;11(9):621–32. doi:10.1038/nrm2952.

    Article  CAS  PubMed  Google Scholar 

  35. Tan L, Kwok RP, Shukla A, Kshirsagar M, Zhao L, Opipari Jr AW, et al. Trichostatin A restores Apaf-1 function in chemoresistant ovarian cancer cells. Cancer. 2011;117(4):784–94. doi:10.1002/cncr.25649.

    Article  CAS  PubMed  Google Scholar 

  36. Shen M, Feng Y, Gao C, Tao D, Hu J, Reed E, et al. Detection of Cyclin B1 Expression in G1-phase cancer cell lines and cancer tissues by postsorting western blot analysis. Cancer Res. 2004;64(5):1607–10. doi:10.1158/0008-5472.can-03-3321.

    Article  CAS  PubMed  Google Scholar 

  37. Zheng H, Hu W, Deavers MT, Shen D-Y, Fu S, Li Y-F, et al. Nuclear cyclin B1 is overexpressed in low-malignant-potential ovarian tumors but not in epithelial ovarian cancer. Am J Obstet Gynecol. 2009;201(4):367.e1-.e6. doi:10.1016/j.ajog.2009.05.021.

    Article  Google Scholar 

  38. Pahl HL. Activators and target genes of Rel/NF-kappaB transcription factors. Oncogene. 1999;18(49):6853–66. doi:10.1038/sj.onc.1203239.

    Article  CAS  PubMed  Google Scholar 

  39. Wang CY, Cusack Jr JC, Liu R, Baldwin Jr AS. Control of inducible chemoresistance: enhanced anti-tumor therapy through increased apoptosis by inhibition of NF-kappaB. Nat Med. 1999;5(4):412–7. doi:10.1038/7410.

    Article  PubMed  Google Scholar 

  40. Annunziata CM, Stavnes HT, Kleinberg L, Berner A, Hernandez LF, Birrer MJ, et al. Nuclear factor kappaB transcription factors are coexpressed and convey a poor outcome in ovarian cancer. Cancer. 2010;116(13):3276–84. doi:10.1002/cncr.25190.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  41. Jin HR, Jin X, Dat NT, Lee JJ. Cucurbitacin B suppresses the transactivation activity of RelA/p65. J Cell Biochem. 2011;112(6):1643–50. doi:10.1002/jcb.23078.

    Article  CAS  PubMed  Google Scholar 

  42. Chan KT, Li K, Liu SL, Chu KH, Toh M, Xie WD. Cucurbitacin B inhibits STAT3 and the Raf/MEK/ERK pathway in leukemia cell line K562. Cancer Lett. 2010;289(1):46–52. doi:10.1016/j.canlet.2009.07.015.

    Article  CAS  PubMed  Google Scholar 

  43. Chan KT, Meng FY, Li Q, Ho CY, Lam TS, To Y, et al. Cucurbitacin B induces apoptosis and S phase cell cycle arrest in BEL-7402 human hepatocellular carcinoma cells and is effective via oral administration. Cancer Lett. 2010;294(1):118–24. doi:10.1016/j.canlet.2010.01.029.

    Article  CAS  PubMed  Google Scholar 

  44. Duangmano S, Sae-Lim P, Suksamrarn A, Patmasiriwat P, Domann FE. Cucurbitacin B causes increased radiation sensitivity of human breast cancer Cells via G2/M Cell Cycle Arrest. J Oncol. 2012;2012:601682. doi:10.1155/2012/601682.

    Article  PubMed  PubMed Central  Google Scholar 

  45. Liu T, Peng H, Zhang M, Deng Y, Wu Z. Cucurbitacin B, a small molecule inhibitor of the Stat3 signaling pathway, enhances the chemosensitivity of laryngeal squamous cell carcinoma cells to cisplatin. Eur J Pharmacol. 2010;641(1):15–22. doi:10.1016/j.ejphar.2010.04.062.

    Article  CAS  PubMed  Google Scholar 

  46. Kaufmann SH, Desnoyers S, Ottaviano Y, Davidson NE, Poirier GG. Specific Proteolytic Cleavage of Poly(ADP-ribose) Polymerase: an early marker of chemotherapy-induced apoptosis. Cancer Res. 1993;53(17):3976–85.

    CAS  PubMed  Google Scholar 

  47. Dantzer F, de la Rubia G, Ménissier-de Murcia J, Hostomsky Z, de Murcia G, Schreiber V. Base excision repair is impaired in mammalian cells lacking poly(adp-ribose) polymerase-1†. Biochemistry. 2000;39(25):7559–69. doi:10.1021/bi0003442.

    Article  CAS  PubMed  Google Scholar 

  48. Bowman KJ, Newell DR, Calvert AH, Curtin NJ. Differential effects of the poly (ADP-ribose) polymerase (PARP) inhibitor NU1025 on topoisomerase I and II inhibitor cytotoxicity in L1210 cells in vitro. Br J Cancer. 2001;84(1):106.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  49. Godoy H, Mhawech-Fauceglia P, Beck A, Miller A, Lele S, Odunsi K. Expression of poly (adenosine diphosphate-ribose) polymerase and p53 in epithelial ovarian cancer and their role in prognosis and disease outcome. Int J Gynecol Pathol: Off J Int Soc Gynecol Pathol. 2011;30(2):139–44. doi:10.1097/PGP.0b013e3181fa5a64.

    Article  Google Scholar 

  50. Michels J, Vitale I, Galluzzi L, Adam J, Olaussen KA, Kepp O, et al. Cisplatin resistance associated with PARP hyperactivation. Cancer Res. 2013;73(7):2271–80. doi:10.1158/0008-5472.CAN-12-3000.

    Article  CAS  PubMed  Google Scholar 

  51. Godwin AK, Meister A, O'Dwyer PJ, Huang CS, Hamilton TC, Anderson ME. High resistance to cisplatin in human ovarian cancer cell lines is associated with marked increase of glutathione synthesis. Proc Natl Acad Sci U S A. 1992;89(7):3070–4.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  52. Gamcsik MP, Kasibhatla MS, Teeter SD, Colvin OM. Glutathione levels in human tumors. Biomarkers. 2012;17(8):671–91. doi:10.3109/1354750X.2012.715672.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  53. Andrews PA, Schiefer MA, Murphy MP, Howell SB. Enhanced potentiation of cisplatin cytotoxicity in human ovarian carcinoma cells by prolonged glutathione depletion. Chem Biol Interact. 1988;65(1):51–8.

    Article  CAS  PubMed  Google Scholar 

  54. Kausar H, Munagala R, Bansal SS, Aqil F, Vadhanam MV, Gupta RC. Cucurbitacin B potently suppresses non-small-cell lung cancer growth: identification of intracellular thiols as critical targets. Cancer Lett. 2013;332(1):35–45. doi:10.1016/j.canlet.2013.01.008.

    Article  CAS  PubMed  Google Scholar 

  55. Burleson K, Hansen L, Skubitz A. Ovarian carcinoma spheroids disseminate on type I collagen and invade live human mesothelial cell monolayers. Clin Exp Metastasis. 2005;21:685-697.

  56. Durand R, Sutherland R. Effects of intercellular contact on repair of radiation damage. Exp Cell Res. 1972;71:75–80.

    Article  CAS  PubMed  Google Scholar 

  57. Filipovich I, Sorokina N, Robillard N, Chatal J. Radiation-induced apoptosis in human ovarian carcinoma cells growing as a monolayer and as multicell spheroids. Int J Cancer. 1997;72:851–9.

    Article  Google Scholar 

  58. Graham C, Kobayashi H, Stankiewicz K, Man S, Kapitain S, Kerbel R. Rapid acquisition of multicellular drug resistance after a single exposure of mammary tumor cells to antitumor alkylating agents. J Natl Cancer Inst. 1994;86:975–82.

    Article  CAS  PubMed  Google Scholar 

  59. Makhija S, Taylor D, Gibb R, Gercel-Taylor. Taxol-induced Bcl-2 phosphorylation in ovarian cancer cell monolayer and spheroids. Int J Oncol. 1999;14:515–21.

    CAS  PubMed  Google Scholar 

  60. Bardies M, Thedrez P, Gestin J, Marcille B, Guerreau D, Faivre-Chauvet A, et al. Use of multi-cell spheroids of ovarian carcinoma as an intraperitoneal radio-immunotherapy model: uptake, retention kinetics and dosimetric evaluation. Int J Cancer. 1992;50:984–91.

    Article  CAS  PubMed  Google Scholar 

  61. Sutherland R, MacDonald H, Howell R. Multicellular spheroids: a new model target for in vitro studies of immunity to solid tumor allografts. J Natl Cancer Inst. 1977;58:1849–53.

    Article  CAS  PubMed  Google Scholar 

  62. Sutherland R, McCredie J, Inch W. Growth of multicell spheroids in tissue culture as a model of nodular carcinoma. J Natl Cancer Inst. 1971;46:113–20.

    CAS  PubMed  Google Scholar 

Download references

Acknowledgments

We would like to thank Lucas Kopel and Mahmoud Salama (Chemistry and Biochemistry Department, South Dakota State University, Brookings, SD, USA). This work was supported by the Egyptian government via the Egyptian Ministry of Higher Education and Scientific Research.

Conflict of interest

None

Authors’ contributions

FE helped in the design of the study, carried out the research, and drafted the manuscript. FB, AE, and FH participated in the design and conceive of the study. SC helped in the design and revision of the draft. All authors read and approved the final manuscript.

Author information

Authors and Affiliations

  1. Department of Chemistry & Biochemistry, South Dakota State University, Brookings, 2202, SD, USA

    Fardous F. El-Senduny & Fathi Halaweish

  2. Pharmacognosy Department, Faculty of Pharmacy, Mansoura University, Mansoura, Egypt

    Farid A. Badria

  3. Chemistry Department, Faculty of Science, Mansoura University, Mansoura, Egypt

    Fardous F. El-Senduny & Ahmed M. EL-Waseef

  4. Department of Pharmaceutical Sciences and Center for Cancer Research, University of Tennessee Health Science Center, Memphis, TN, USA

    Subhash C. Chauhan

Authors
  1. Fardous F. El-Senduny
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Farid A. Badria
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ahmed M. EL-Waseef
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Subhash C. Chauhan
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Fathi Halaweish
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Fathi Halaweish.

Electronic supplementary material

Below is the link to the electronic supplementary material.

ESM 1

(DOCX 2.30 MB)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

El-Senduny, F.F., Badria, F.A., EL-Waseef, A.M. et al. Approach for chemosensitization of cisplatin-resistant ovarian cancer by cucurbitacin B. Tumor Biol. 37, 685–698 (2016). https://doi.org/10.1007/s13277-015-3773-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13277-015-3773-8

Keywords

Search

Navigation